Company Overview
BioRestorative Therapies, Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry where it develops therapeutic products and medical therapies utilizing cell and tissue protocols primarily involving adult stem cells. The company's core mission involves creating programs related to the treatment of disc and spine disease as well as metabolic disorders, with its product pipeline including BRTX-100. This biotechnology entity currently employs 11 individuals to execute its research and development initiatives. With a market capitalization of $6.42M and annual revenue of $383,400, the company operates on a very small scale relative to established large-cap pharmaceutical peers. These valuation and revenue figures indicate that BioRestorative Therapies, Inc. is a micro-cap entity with limited financial resources, suggesting that its business model relies heavily on capital efficiency and successful clinical trial outcomes to achieve commercial viability.
Financial Health
The company reported revenue of $383,400 over the trailing twelve months, yet it recorded a net income of $-12,670,487 and an EBITDA of $-14,304,456. The substantial gap between the positive revenue figure and the significantly negative net income reveals an extremely aggressive cost structure where operating expenses far exceed current sales generation. Free cash flow stands at $-6,757,906, indicating that the company is burning through its available capital reserves to fund its development activities rather than generating internal cash. Gross margin is reported at 93.3%, which suggests high gross efficiency in producing its cell therapy products before accounting for operational overheads. Conversely, the operating margin is -31432.3% and the profit margin is 0.0%, highlighting that fixed costs and R&D expenditures are disproportionately high relative to the current revenue base. The company holds $4.49M in cash and has N/A debt, resulting in a debt-to-equity ratio of N/A. The absence of recorded debt suggests a conservative balance sheet approach, though the reliance on cash reserves to cover losses is a critical liquidity constraint. The current ratio is 1.37, which indicates that the company has sufficient current assets to cover its short-term liabilities, providing a buffer for its immediate operational needs. Return on equity is -207.7% and return on assets is -89.7%, metrics that reveal management is currently unable to generate positive returns on the capital invested in the business.
Valuation Assessment
The P/E Ratio (TTM) is N/A due to the lack of net income, while the forward P/E is -0.31, implying that market expectations for future earnings remain deeply negative or that earnings are projected to be negligible. The price-to-book ratio is 1.08, which indicates that the market values the company slightly above its book value despite its current lack of profitability. The price-to-sales ratio is 16.75, a metric that is often used for pre-profitable biotechnology firms, suggesting that the market is pricing in significant future growth potential from its pipeline. Additionally, the EV/EBITDA is 0.13, which is an alternative valuation metric that reflects the company's enterprise value relative to its earnings before interest, taxes, depreciation, and amortization. The stock has traded between a 52-week high of $2.10 and a 52-week low of $0.19, providing a range within which the current share price fluctuates. The beta value is 0.41, indicating that the stock exhibits lower price volatility relative to the broader market and is generally less sensitive to general market movements.
Growth & Income
Revenue growth year-over-year is -94.9%, while earnings growth year-over-year is N/A due to the company's recent losses. The negative revenue growth indicates a contraction in sales, whereas the absence of earnings growth data reflects the company's transition phase where it has not yet achieved profitability. Regarding dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company does not distribute any portion of its earnings to shareholders. Instead of paying dividends, the company retains all earnings and cash reserves to reinvest into its research and development programs and to extend its runway for clinical trials. The overall growth and income profile for BioRestorative Therapies, Inc. is characterized by significant revenue contraction and a complete absence of dividend income, relying entirely on capital markets or cash reserves to fund its ongoing operations.